Genetic Immunity, InPlay Completes Patient Enrollment In Phase II …Medical News Today (press release), UKWith this trial we plan to demonstrate the safety and efficacy of DermaVir Patch as monotherapy administered every 6 weeks for the treatment of HIV," commented Julianna Lisziewicz, CEO of Genetic Immunity. This novel plasmid DNA-based nanomedicine …
Original post by dna genetic – Google News and software by Elliott Back